This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Biosimilar Humira, biosimilar adalimumab
Exemptia is a biosimilar to Abbvie's Humira.
Humira (adalimumab) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF). Humira binds specifically to TNF-alpha and blocks interaction with the p55 and p75 cell surface TNF receptors. Humira also lyses surface TNF expressing cells in the presence of complement.
Additional information available to subscribers only: